Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* History of jet lag symptoms during the past 5 years.~* The subject is in good health, as determined by a medical and psychiatric history, medical examination, clinical laboratory test results, and electrocardiography (ECG) and physical examination findings.~* Women of childbearing potential must be abstinent or use a medically accepted method of contraception, and must continue use of this method for the duration of the study (and for 30 days after participation in the study).~* The subject is willing to comply with study restrictions and remain at the study center overnight, as required.~* The subject must agree to refrain from alcohol use during the study.~* The subject has a valid U.S. passport~Key Exclusion Criteria:~* The subject has a history (past 12 months) or diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), shift work sleep disorder (SWSD), or any other sleep disorder associated with excessive daytime sleepiness; or the subject has a history or current diagnosis of hypersomnia, insomnia, or sleep disorder.~* The subject has any serious acute or chronic cardiovascular, pulmonary, gastrointestinal, neurological, endocrine or renal illness (including diabetes mellitus), hepatitis, asthma, chronic obstructive pulmonary disease (COPD), or any other clinically relevant significant medical condition.~* The subject has a history of any cutaneous drug reaction or drug hypersensitivity, or any clinically significant hypersensitivity reaction, or multiple allergies.~* The subject has a history of deep vein thrombosis (DVT).~* The subject has known human immunodeficiency virus (HIV).~* The subject is pregnant or lactating.~* The subject has used nicotine within the last 3 months.~* The subject has a history of seizures, except for a single febrile seizure.~* The subject has a psychiatric disorder that would affect participation in the study or full compliance with study procedures.~* The subject has a clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings.~* The subject used any prescription or over the counter drugs disallowed by the protocol within 7 days of screening visit 2 (i.e., stimulants, hypnotics).~* The subject has used an investigational drug within 1 month before the screening visit.~* The subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion.~* The subject has a known hypersensitivity to armodafinil or modafinil, or any other component of the study drug tablets.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): armodafinil - dosage of 50 mg/day
- 2 (Type: EXPERIMENTAL): armodafinil - dosage of 150 mg/day
- 3 (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete